Palbociclib Demonstrates Activity in Acral Lentiginous Melanoma Subtype

Published: Wednesday, Jun 12, 2019
The CDK4/6 inhibitor palbociclib (Ibrance) exhibited preliminary activity in patients with acral lentiginous melanoma (ALM) associated with CDK-pathway aberrations, according to results of a small phase II trial that were reported at the 2019 ASCO Annual Meeting.

Most recently, the FDA expanded the approval of palbociclib capsules in combination with endocrine therapy to include male patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Mao L, Cao Y, Sheng X, et al. Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations. J Clin Oncol. 2019;37(suppl; abstr 9528).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication